

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Jochen G. Salfeld *et al.*

Serial No.: 09/540,018

Filed: March 31, 2000

For: HUMAN ANTIBODIES THAT BIND TNF $\alpha$ 

Attorney Docket No.: BBI-043CPACN

Group Art Unit: 1641


Examiner: D. Saunders

Commissioner for Patents  
Washington, D.C. 20231Certificate of Facsimile Transmission

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner for Patents, Washington, DC 20231 on the date set forth below.

June 28, 2001  
Date

By:

  
Elizabeth A. Hanley, Reg. No. 33,505  
Attorney for ApplicantsPRELIMINARY AMENDMENT

Dear Sir:

Prior to examination of the patent application identified above, please amend the claims as follows:

Please cancel ~~claim~~ 1.

Please add the following new claims:

1 ~~55~~. (New) A method for inhibiting human TNF $\alpha$  activity comprising contacting human TNF $\alpha$  with an antibody such that human TNF $\alpha$  activity is inhibited, wherein the antibody is an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNF $\alpha$  with a  $K_d$  of  $1 \times 10^{-8}$  M or less and a  $K_{off}$  rate

B1

59

B